These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17991300)

  • 1. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate.
    Ingle GS; Chan P; Elliott JM; Chang WS; Koeppen H; Stephan JP; Scales SJ
    Br J Haematol; 2008 Jan; 140(1):46-58. PubMed ID: 17991300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
    Gerber HP; Kung-Sutherland M; Stone I; Morris-Tilden C; Miyamoto J; McCormick R; Alley SC; Okeley N; Hayes B; Hernandez-Ilizaliturri FJ; McDonagh CF; Carter PJ; Benjamin D; Grewal IS
    Blood; 2009 Apr; 113(18):4352-61. PubMed ID: 19147785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
    Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
    Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
    Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
    Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
    J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.
    Lee Y; Haas KM; Gor DO; Ding X; Karp DR; Greenspan NS; Poe JC; Tedder TF
    J Immunol; 2005 Dec; 175(12):8011-23. PubMed ID: 16339538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis.
    Mongini PK; Jackson AE; Tolani S; Fattah RJ; Inman JK
    J Immunol; 2003 Nov; 171(10):5244-54. PubMed ID: 14607925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance.
    Otsuka M; Yakushijin Y; Hamada M; Hato T; Yasukawa M; Fujita S
    Br J Haematol; 2004 Nov; 127(4):416-24. PubMed ID: 15521918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
    Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
    J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
    Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
    J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to lymphocyte surface antigens for cetacean homologues to CD2, CD19 and CD21.
    De Guise S; Erickson K; Blanchard M; DiMolfetto L; Lepper HD; Wang J; Stott JL; Ferrick DA
    Vet Immunol Immunopathol; 2002 Jan; 84(3-4):209-21. PubMed ID: 11777535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
    Chang CA; Emberley E; D'Souza AL; Zhao W; Cosgrove C; Parrish K; Mitra D; Payson E; Oleksijew A; Ellis P; Rodriguez L; Duggan R; Hrusch C; Lasko L; Assaily W; Zheng P; Liu W; Hernandez A; McCarthy K; Zhang Z; Rha G; Cao Z; Li Y; Perng O; Campbell J; Zhang G; Curran T; Bruncko M; Marvin CC; Hobson A; McPherson M; Uziel T; Pysz MA; Zhao X; Bankovich A; Hayflick J; McDevitt M; Freise KJ; Morgan-Lappe S; Purcell JW
    Blood; 2024 Aug; 144(7):757-770. PubMed ID: 38701407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation.
    Gommerman JL; Oh DY; Zhou X; Tedder TF; Maurer M; Galli SJ; Carroll MC
    J Immunol; 2000 Dec; 165(12):6915-21. PubMed ID: 11120817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
    Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
    Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
    Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
    Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
    Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD21 and CD19 deficiency: Two defects in the same complex leading to different disease modalities.
    Wentink MW; Lambeck AJ; van Zelm MC; Simons E; van Dongen JJ; IJspeert H; Schölvinck EH; van der Burg M
    Clin Immunol; 2015 Dec; 161(2):120-7. PubMed ID: 26325596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19 can regulate B lymphocyte signal transduction independent of complement activation.
    Hasegawa M; Fujimoto M; Poe JC; Steeber DA; Tedder TF
    J Immunol; 2001 Sep; 167(6):3190-200. PubMed ID: 11544305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.